Angel investor
Every published round David Williams took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Project Manda | Pre-seed | 28 Mar 2025 | $2m+ | Participant | SmartCompany |
Companies David Williams has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Project Manda | 28 Mar 2025, Pre-seed | 1 | 0 |
Fund closes reported for David Williams, as distinct from the investments it has made.
Companies David Williams has backed that another company then bought. An exit for the holding, not a deal David Williams did.
| Role | Organisation | Sources |
|---|---|---|
| No role recorded yet. David Williams has been mentioned, but not yet attached to an organisation. Know their role? | ||
Stories naming David Williams. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Arovella Therapeutics has produced its first clinical batch of ALA-101, a donor-derived cell therapy for blood cancer, and begun trials at a Melbourne hospital, with the first patient expected to be dosed this month.
Project Manda, whose AI platform trims wasteful meetings, has collected more than $2 million at pre-seed, with Tech Labs Capital and Black Sheep Capital leading, as it eyes the US market.